Cell and gene therapy CDMO Minaris Regenerative Medicine has announced a $64.5m to significantly expand its facilities in Europe and Asia.
European facility expansion: A new facility will be built in the proximity of the existing site in Ottobrunn near Munich, Germany with a total investment of $40.7m. The new facility will operate according to GMP standards (FDA and EMA) and be dedicated to clinical and commercial manufacturing as well as development services for cell and gene therapies.
The multi-storey building with a total of 6,650 sqm will initially more than double Minaris existing capacity in Europe by providing additional cleanrooms, quality control laboratories, warehousing, cryo-storage and office space.
It will have a modular design with the possibilities to go from single room to ball room design and to flexibly change between grade B and grade C configuration.
The new facility is expected to be operational early 2023 and will allow for additional expansion of cleanrooms according to client demand and specifications, thus more than tripling the current cleanroom capacity.
"We are very pleased to expand our capacity to support the growing demand of clients who continue to care for an increasing number of patients in the future", said Dusan Kosijer, Managing Director of Minaris.
Asian site expansion: A new facility will also be established adjacent to the existing facility in Yokohama, Japan allowing for an additional 4,000 sqm which will double the capacity for commercial manufacturing of regenerative medicine.
The new facility is scheduled to start operations in October 2022. The investment of $23.8m is part of a strategy to establish a centre for cancer immunotherapy and somatic stem cells.
The European and Asian expansions complement the opening of the new commercial facility in Allendale, New Jersey, USA announced in January this year.
